KURA — Kura Oncology, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1422143 ·
Last close
$12.40
Market Cap
$1.10B
52W High
$12.90
52W Low
$8.39
ADV30
1,616,686
Next earnings
2026-11-03
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 18,265,000 18,003,000 -78,815,000 -73,333,000 652,551,000 39,083,000 544,668,000
Dec 2025 17,336,000 -86,268,000 -80,999,000 738,363,000 149,099,000 564,228,000
Sep 2025 20,750,000 -79,997,000 -74,116,000 649,381,000 95,287,000 406,839,000
Jun 2025 15,288,000 -72,666,000 -66,122,000 682,425,000 81,948,000 376,939,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-77,985,000
Investing CF
$64,080,000
Financing CF
$1,719,000
CapEx
$-6,474,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.35
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,247,421,000
Inventory
$843,000
Receivables
$9,348,000
ST Investments
$541,740,000
EBIT TTM
$-293,025,000
Pretax Income TTM
$-294,491,000
Interest Exp TTM
$1,466,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$77,225,000
EBITDA
$-316,799,008
Free Cash Flow
$-165,880,752
Enterprise Value
$563,171,776
Total Cash
$519,024,992
Total Debt
$24,455,000
Shares Out
88,960,619
Trailing EPS
$-3.37
Book Value
$0.54
ROE
-167.7%
ROA
-31.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 67,482,000 -303,631,000 -278,666,000 738,363,000 564,228,000 -64,058,000
Dec 2024 53,883,000 -193,195,000 -173,983,000 760,159,000 346,519,000 134,317,000
Dec 2023 0 -165,804,000 -152,631,000 448,935,000 51,662,000 -124,824,000
Dec 2022 0 -139,865,000 -135,840,000 456,306,000 36,028,000 -110,062,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.25

Max Pain — expiry 2027-01-15

max pain strike: $12.00 · spot: $12.40 · call oi: 1,426 · put oi: 1,737
Expected Move to 2027-01-15: ±$4.30 (34.68%) — implied range $8.10$16.70 · ATM straddle on $12.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
OPK OPKO HEALTH, INC. $1.10B $1.48
IVA Inventiva S.A. $1.11B $4.70
JANX Janux Therapeutics, Inc. $1.14B $18.60
SVRA Savara Inc $1.14B $5.56
OBX Obsidian Therapeutics, Inc. $1.16B $18.70

News headlines (Yahoo Finance, 1h cache)

Kura Oncology (KURA) Q2 2026 Earnings Call Transcript
2026-08-19 20:59 · Yahoo
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?
2026-08-18 13:55 · Yahoo
Why Is KURA Stock Rallying 8% After-Hours?
2026-08-17 22:28 · Yahoo
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
2026-08-12 21:40 · Yahoo
Kura Oncology Reports Second Quarter 2026 Financial Results
2026-08-12 20:02 · Yahoo
Kura Oncology Reports 50% Response Rate in RCC Combination Study
2026-07-27 16:01 · Yahoo
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
2026-07-14 11:02 · Yahoo
Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story?
2026-07-07 22:09 · Yahoo
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-03 11:30 · Yahoo
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
2026-06-11 12:02 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-08-24 17:30:03 2026-08-24 Wilson Troy Edward Pres, CEO P - Purchase 12.39 100000 1239000